FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2172924976> ?p ?o ?g. }

• W2172924976 abstract "Abstract High-level expression of fetal (Υ) globin reduces clinical complications in sickle cell disease and this is achieved with hydroxyurea (HU) in young children. However, non-cytotoxic high-potency therapeutics, particularly which can be utilized in combination with HU, are needed for most adolescent and adult patients who have continued serious clinical events. We have identified additional pharmaceutical candidates which induce HbF without cytotoxicity, using a Υ-globin gene promoter linked to GFP for robotic high-throughput screening, and screening five diverse chemical libraries. From a library of US and EU drugs which are approved for treatment of other medical conditions, a small panel of approved therapeutics were found to induce Υ globin expression, and have benign safety profiles, are orally active, and are suitable for long-term use. Three orally active candidates were evaluated in anemic baboons, and two, DLT and PB-04, induced Υ-globin mRNA by 15- to 33-fold over baseline levels. In 3/3 beta-globin locus YAC transgenic mice, one candidate (PB-04; 20 mg/kg) given by intra-peritoneal (IP) injections (for experimental feasibility) 3 times/ week for 5 wks significantly increased F-cells from 0.1 to 9%, 0.4 to 18%, and 0.13 to 12% respectively; and mean fluorescence intensity (MFI) increased by 10- to 33-fold. Responses were observed within one week. In hydroxyurea treated mice (100 mg/kg; IP, 5 days/ wk) F-cells increased from 0.3 to 2.3% on average (p<0.05), and MFI increased by 6- to 7-fold, while water vehicle did not increase F-cells significantly. PB-04 has been used clinically for decades as an excipient solely to prolong the half-life of another pharmaceutical, and is suitable for repurposing. In ChIP assays in K562 cells, PB-04 treatment demonstrated dual actions of displacing HDAC3 by 20-fold and LSD-1 by 3-fold from the Υ globin gene promoter. To investigate potential effects of genetic modifiers of HbF on responses to different HbF inducer classes, erythroid progenitors from 40 sickle and beta thalassemic subjects were sub-genotyped for 3 major quantitative trait loci (QTL) (Bcl-11A, HMIP, Xmn-I) and cultured +/- 7 HbF inducers which are in clinical trials or approved. Most HbF inducers, including decitabine and butyrate used as positive controls, are active in 50-70% of progenitors, with differential Υ-globin mRNA responses observed. Only 10% of progenitors did not respond to any inducing agent. Most progenitors with the Xmn-1 variant responded with higher Υ globin transcription to all inducers. Sodium dimethylbutyrate (HQK-1001) and decitabine, produced 6-fold overall mean induction. PB-04 produced 9-fold mean induction above untreated control levels from the same subject. HDAC inhibitors (Butyrate, MS-275) which suppress Bcl-11A expression, demonstrate higher activity in progenitors from subjects without an underlying SNP in Bcl-11A. Another HDAC inhibitor, SB939, produced responses in 80% of progenitors. 25-30% of subjects’ progenitors exhibit high induction, 12-to 40-fold above untreated controls, to dimethylbutyrate, PB-04, decitabine, and an HDAC1/2 inhibitor 14F, suggesting a “high responder genotype” of which only half had a recognized favorable QTL. Taken together, these in vitro and in vivo studies identify a mini-pipeline of clinical-stage HbF-inducing therapeutics, with both epigenetic and targeted molecular actions, which can be investigated clinically to develop tailored therapeutics and therapeutic combinations for high-level induction of HbF in subgenotyped hemoglobinopathy patients. Seven new and established inducers have been evaluated in erythroid progenitors cultured from sub-genotyped hemoglobinopathy patients, 3 new drugs (PB-04, DLT, RSV) and two HDAC inhibitors (MS-275 and SB939), induced 3- to 40-fold higher Υ-globin mRNA above untreated control levels. Disclosures: Faller: Phoenicia BioSciences, Inc.: Employment, Equity Ownership, Membership on an entity’s Board of Directors or advisory committees, Research Funding. Perrine:Phoenicia BioSciences, Inc.: Employment, Equity Ownership, Membership on an entity’s Board of Directors or advisory committees, Research Funding." @default.
• W2172924976 created "2016-06-24" @default.
• W2172924976 creator A5022759647 @default.
• W2172924976 creator A5032470452 @default.
• W2172924976 creator A5044458439 @default.
• W2172924976 creator A5046490615 @default.
• W2172924976 creator A5047011210 @default.
• W2172924976 creator A5058096595 @default.
• W2172924976 creator A5063733324 @default.
• W2172924976 creator A5068018268 @default.
• W2172924976 creator A5083735394 @default.
• W2172924976 creator A5086539163 @default.
• W2172924976 date "2013-11-15" @default.
• W2172924976 modified "2023-09-29" @default.
• W2172924976 title "Next Generation Clinical-Stage HbF Inducers Exhibit Multiple Molecular Actions In Vitro and In Vivo and Offer Personalized Therapeutic Regimens" @default.
• W2172924976 doi "https://doi.org/10.1182/blood.v122.21.560.560" @default.
• W2172924976 hasPublicationYear "2013" @default.
• W2172924976 type Work @default.
• W2172924976 sameAs 2172924976 @default.
• W2172924976 citedByCount "1" @default.
• W2172924976 countsByYear W21729249762014 @default.
• W2172924976 crossrefType "journal-article" @default.
• W2172924976 hasAuthorship W2172924976A5022759647 @default.
• W2172924976 hasAuthorship W2172924976A5032470452 @default.
• W2172924976 hasAuthorship W2172924976A5044458439 @default.
• W2172924976 hasAuthorship W2172924976A5046490615 @default.
• W2172924976 hasAuthorship W2172924976A5047011210 @default.
• W2172924976 hasAuthorship W2172924976A5058096595 @default.
• W2172924976 hasAuthorship W2172924976A5063733324 @default.
• W2172924976 hasAuthorship W2172924976A5068018268 @default.
• W2172924976 hasAuthorship W2172924976A5083735394 @default.
• W2172924976 hasAuthorship W2172924976A5086539163 @default.
• W2172924976 hasConcept C126322002 @default.
• W2172924976 hasConcept C172680121 @default.
• W2172924976 hasConcept C202751555 @default.
• W2172924976 hasConcept C207001950 @default.
• W2172924976 hasConcept C2776317666 @default.
• W2172924976 hasConcept C2779234561 @default.
• W2172924976 hasConcept C54355233 @default.
• W2172924976 hasConcept C57992300 @default.
• W2172924976 hasConcept C71924100 @default.
• W2172924976 hasConcept C86803240 @default.
• W2172924976 hasConcept C98274493 @default.
• W2172924976 hasConceptScore W2172924976C126322002 @default.
• W2172924976 hasConceptScore W2172924976C172680121 @default.
• W2172924976 hasConceptScore W2172924976C202751555 @default.
• W2172924976 hasConceptScore W2172924976C207001950 @default.
• W2172924976 hasConceptScore W2172924976C2776317666 @default.
• W2172924976 hasConceptScore W2172924976C2779234561 @default.
• W2172924976 hasConceptScore W2172924976C54355233 @default.
• W2172924976 hasConceptScore W2172924976C57992300 @default.
• W2172924976 hasConceptScore W2172924976C71924100 @default.
• W2172924976 hasConceptScore W2172924976C86803240 @default.
• W2172924976 hasConceptScore W2172924976C98274493 @default.
• W2172924976 hasLocation W21729249761 @default.
• W2172924976 hasOpenAccess W2172924976 @default.
• W2172924976 hasPrimaryLocation W21729249761 @default.
• W2172924976 hasRelatedWork W1941525738 @default.
• W2172924976 hasRelatedWork W2002870825 @default.
• W2172924976 hasRelatedWork W2022365217 @default.
• W2172924976 hasRelatedWork W2133577996 @default.
• W2172924976 hasRelatedWork W2519519223 @default.
• W2172924976 hasRelatedWork W2559662107 @default.
• W2172924976 hasRelatedWork W2566638468 @default.
• W2172924976 hasRelatedWork W2586089761 @default.
• W2172924976 hasRelatedWork W2587005064 @default.
• W2172924976 hasRelatedWork W2592667147 @default.
• W2172924976 hasRelatedWork W2602335820 @default.
• W2172924976 hasRelatedWork W2730478620 @default.
• W2172924976 hasRelatedWork W2751645476 @default.
• W2172924976 hasRelatedWork W2902100946 @default.
• W2172924976 hasRelatedWork W2921252644 @default.
• W2172924976 hasRelatedWork W2979497126 @default.
• W2172924976 hasRelatedWork W3093261528 @default.
• W2172924976 hasRelatedWork W3095445729 @default.
• W2172924976 hasRelatedWork W3103960073 @default.
• W2172924976 hasRelatedWork W3139300979 @default.
• W2172924976 isParatext "false" @default.
• W2172924976 isRetracted "false" @default.
• W2172924976 magId "2172924976" @default.
• W2172924976 workType "article" @default.